The Study of Efficacy and Safety of a 60-day Use of the Magnox Comfort Compared to the Placebo in Subjects With NLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
At the beginning of the study, study subjects undergo a 14‐day screening period during which the number of episodes of NLC is recorded. For further participation in the study, they must have at least 4 NLC episodes. Thereafter, an examination of compliance with the study requirements is performed and study subjects are randomized to one of the two groups: for a 60‐day of IP use (1 capsule of Magnox Comfort daily) or to the control group (1 capsule of placebo daily).
Epistemonikos ID: 45e1f49d9de70aa15411980ff8aab96bcbb83a0f
First added on: May 21, 2024